Targeted complement inhibitors (e.g., C5a inhibitors)

Type: drug

Status: FDA Approved

Developer: ChemoCentryx (now Amgen)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026